Browse > Article
http://dx.doi.org/10.22722/KJPM.2021.29.2.153

Comparison of Bleeding Tendency Between Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Using Platelet Function Analyzer  

Koo, Seung Mo (Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine)
Kim, Hyun (Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine)
Lee, Kang Joon (Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine)
Publication Information
Korean Journal of Psychosomatic Medicine / v.29, no.2, 2021 , pp. 153-161 More about this Journal
Abstract
Objectives : The purpose of this study is to compare bleeding tendency of selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) using platelet function analyzer (PFA-100) in patients with major depressive disorder. Methods : This study is a prospective open-label study conducted by a single institution. A total of 41 subjects diagnosed with major depressive disorder under the DSM-5 diagnostic criteria participated in this study. The subjects were classified into SSRI (escitalopram) groups and SNRI (duloxetine) groups, respectively, according to random assignments. The closure time (CT) was measured using a platelet function analyzer (PFA-100) before each antidepressant was administered and after 6 weeks. Paired-sample t-test was conducted within each group to determine whether a specific antidepressant had an effect on closure time. In order to confirm the relative change in platelet function between the two groups, an independent sample t-test was conducted to compare and analyze the change in closure time between the two groups. Results : There was no significant changes in closure time (CEPI-CT, CADP-CT) before and 6 weeks after drug administration in the SSRI and SNRI groups, and there was no difference in the amount of changes in closure time between the two groups. Conclusions : Our results showed no difference in bleeding tendency between SSRI and SNRI. This study suggests that further large-scale studies on bleeding tendency for various antidepressants are needed in the future.
Keywords
Platelet function analyzer (PFA-100); Bleeding tendency; Selective Serotonin Reuptake Inhibitor; Serotonin Norepinephrine Reuptake Inhibitor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 2011;89:89-96.   DOI
2 Kim SJ. Prescription pattern of antidepressants among the Korean patients with depression (thesis). Seoul: Seoul National University;2018.
3 Kotzailias N, Andonovski T, Dukic A, Serebruany VL, Jilma B. Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. J Clin Pharmacol 2006;46:468-475.   DOI
4 Sajan F, Conte JV, Tamargo RJ, Riley LH, Rock P, Faraday N. Association of selective serotonin reuptake inhibitors with transfusion in surgical patients. Anesth Analg 2016;123:21-28.   DOI
5 Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother 1996; 30:1232-1234.   DOI
6 Menys VC, Smith CC, Lewins P, Farmer RD, Noble MI. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci (Lond) 1996;91:87-92.   DOI
7 Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.   DOI
8 Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.   DOI
9 Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340: 249-258.   DOI
10 World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organization;2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf.
11 American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, ed 3. Arlington: American Psychiatric Association; 2010. Available from: http://www.psych.org/guidelines/mdd2010.
12 De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999;319:1106-1109.
13 Lederbogen F, Weber B, Colla M, Heuser H, Deuschle M, Dempfle CE. Antidepressant treatment and global tests of coagulation and fibrinolysis. J Clin Psychiatry 2001;62:2.
14 Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-140   DOI
15 Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004;164:2367-2370.   DOI
16 Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-415.   DOI
17 Quinn GR, Hellkamp AS, Hankey GJ, Becker RC, Berkowitz SD, Breithardt G, Fava M, Fox KAA, Halperin JL, Mahaffey KW, Nessel CC, Patel MR, Piccini JP, Singer DE. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF trial. J Am Heart Assoc 2018;7:e008755.   DOI
18 McCloskey DJ, Postolache TT, Vittone BJ, Nghiem KL, Monsale JL, Wesley RA, Rick ME. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008;151:168-172.   DOI
19 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789-1858.   DOI
20 Abdelmalik N, Ruhe HG, Barwari K, van den Dool EJ, Meijers JC, Middeldorp S, Buller HR, Schene AH, Kamphuisen PW. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 2008; 6:2168-2174.   DOI
21 Harrison P, Robinson M, Liesner R, Khair K, Cohen H, Mackie I, Machin S. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 2002;24:225-232.   DOI
22 Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res 2017; 118:19-32.   DOI
23 Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM; Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-944.   DOI
24 Organization for Economic Co-operation and Development. Health at a Glance 2017: OECD Indicators. Paris: OECD Publishing;2017. Available from: https://doi.org/10.1787/health_glance-2017-en.   DOI
25 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.   DOI
26 Rui P, Hing E, Okeyode T. National Ambulatory Medical Care Survey: 2014 state and national summary tables. Available from: https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2014_namcs_web_tables.pdf.
27 Lee KK. Adverse effects and pharmacological management of newer antidepressants: focusing on common but under-recognized adverse effect. Korean J Psychopharmacol 2014;25:11-20
28 Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009;7:1314-1321.   DOI
29 Park SC, Sung SH, Han KM, Won ES, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, Lee KJ, Han CS, Ham BJ, Choi JH, Lee HY, Hwang TY, Oh KS, Park YC, Lee MS, Hahn SW. Evidence-based Korean pharmacological treatment guideline for depression, revised edition (I): initial choice of antidepressant treatment. J Korean Neuropsychiatr Assoc 2013;52:253-262.   DOI
30 Atar D, Malinin A, Pokov A, van Zyl L, Frasure-Smith N, Lesperance F, Serebruany VL. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a doseranging in vitro study. Neuropsychopharmacology 2007;32: 2369-2374.   DOI
31 Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007;9:47-59.   DOI
32 Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010;340:c1468.   DOI
33 Khawam EA, Laurencic G, Malone DA Jr. Side effects of antidepressants: an overview. Cleve Clin J Med 2006;73:351- 353, 356-361.   DOI
34 Powell KK, Wang W, Kelleher KJ, O'Brien SH. Use of SSRIs not associated with increased bleeding events in children: an analysis of the michigan medicaid database from 2000-2003. Blood 2008;112:2389.   DOI
35 Laine-Cessac P, Shoaay I, Garre JB, Glaud V, Turcant A, Allain P. Study of haemostasis in depressive patients treated with fluoxetine. Pharmacoepidemiol Drug Saf 1998;7(suppl1):S54-S57.   DOI
36 Laursen SB, Leontiadis GI, Stanley AJ, Hallas J, Schaffalitzky de Muckadell OB. The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. Aliment Pharmacol Ther 2017;46:355-363.   DOI
37 Pletscher A. Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Br J Pharmacol Chemother 1968; 32:1-16.   DOI
38 De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990;8 Suppl 3:40-49.
39 De Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011;28:345-367.   DOI
40 Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81.   DOI
41 Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, Ferguson JJ, O'Connor CM. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003;5:517-521.   DOI
42 De Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008;65:795-803.   DOI
43 Cheng YL, Hu HY, Lin XH, Luo JC, Peng YL, Hou MC, Lin HC, Lee FY. Use of SSRI, But Not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore) 2015; 94:e2022.   DOI
44 Francis J, Francis D, Larson L, Helms E, Garcia M. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets 1999;10:132-136.   DOI
45 Buyukasik Y, Karakus S, Goker H, Haznedaroglu IC, Ozatli D, Sayinalp N, Ozcebe OI, Dundar SV, Kirazli S. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 2002;13:349-353.   DOI
46 Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68:435-442.   DOI
47 Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003;163:2354-2358.   DOI
48 Castro VM, Gallagher PJ, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012;2:e000544.   DOI
49 Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005;130: 759-767.   DOI
50 Cho YU, Chi HS, Jang S, Park CJ. Reconfirmation of preanalytical variables and establishment of reference intervals of platelet function analyzer-100 closure times in Korean adults. Korean J Lab Med 2007;27:318-323.